Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: A longitudinal study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1150-1154

  Maggi, Paolo ^a   Montinaro, Vincenzo ^a   Leone, Armando ^a   Fasano, Massimo ^a   Volpe, Anna ^a   Bellacosa, Chiara ^a   Grattagliano, Vito ^a   Coladonato, Laura ^a   Lapadula, Giovanni ^a   Santantonio, Teresa ^b   Angarano, Gioacchino ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Adefovir; Bone toxicity; Hepatitis B; Tenofovir

Indexed keywords

25 HYDROXYVITAMIN D; ADEFOVIR; COLECALCIFEROL; LAMIVUDINE; PARATHYROID HORMONE; TENOFOVIR; VITAMIN D; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TOXICITY; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS VARICES; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEMATURIA; HEMOGLOBINURIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PROTEINURIA; TOXICITY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; AGED; ANALOGS AND DERIVATIVES; BONE DISEASES; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS B, CHRONIC; KIDNEY DISEASES; PATHOLOGY;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; BONE DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HEMATURIA; HEPATITIS B, CHRONIC; HUMANS; HYPOPHOSPHATEMIA; KIDNEY DISEASES; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROTEINURIA; VITAMIN D DEFICIENCY;

EID: 84926460470     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku502     Document Type: Article

References (21)

1. Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf 2011; 10: 809-18.
2. Izzedine H, Harris M, Perazella M. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009; 5: 563-73.
3. Ray A, Cihlar T, Robinson K et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-304.
4. Gallant J, Staszewski S, Pozniak A et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. JAMA 2004; 292: 191-201.
5. Gallant J, Dejesus E, Arribas J et al. Tenofovir DT, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
6. Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at 48 weeks. AIDS 2008; 22: 1389-97.
7. Molina J, Podsadecki T, JohnsonMet al. A lopinavir/ritonavir based oncedaily regimen results in better compliance and is noninferior to a twicedaily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23:1505-14.
8. Szczech L. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med 2008; 16: 122-6.
9. Winston J. HIV and CKD epidemiology. Adv Chronic Kidney Dis 2010; 17: 19-25.
10. Vigneau C, Guiard-Schmid J, Tourret J et al. The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002. Kidney Int 2005; 67: 1509-14.
11. Marcellin P, Gane EJ, Tsai N et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013; 4: 649A.
12. Lampertico P, Mangia G, Viganò M et al. High rates of tenofovir dose adjustments are required in adefovir experienced patients with chronic hepatitis B: a 4-years prospective study in 320 patients. Dig Liver Dis 2014; 46: e49.
13. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
14. Brown GR, Greenwood JK. Drug-and nutrition-induced hypophosphatemia:mechanisms and relevance in the critically ill. Ann Pharmacother 1994; 28: 626-32.
15. Thomas D. DuBose. Proceedings of the American Society of Nephrology, San Diego, CA, 2006. Presidential Address.
16. Di Paolo N. Studio epidemiologico delle malattie renali nella provincia di Siena: risultati dello screening di massa. In: Epidemiologia delle malattie renali. Milan, Italy: Wichtig, 1991; 179-214.
17. Bettica P, Bevilacqua M, Vago T et al. High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteoporos Int 1999; 9: 226-9.
18. Horberg M, Tang B, Towner Wet al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53: 62-9.
19. Fung J, Seto WK, Lai CL et al. Extra-hepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol 2014; 29: 428-34.
20. Buchacz K, Brooks JT, Tong T et al. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 2006; 7: 451-6.
21. Masiá M, Padilla S, Robledano C et al. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses 2012; 28: 242-6.